FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease


Por: Garcia-Recio S, Thennavan A, East M, Parker J, Cejalvo J, Garay J, Hollern D, He X, Mott K, Galvan P, Fan C, Selitsky S, Coffey A, Marron D, Braso-Maristany F, Burgues O, Albanell J, Rojo F, Lluch A, de Duenas E, Rosen J, Johnson G, Carey L, Prat A, Perou C

Publicada: 1 sep 2020
Resumen:
Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative (cHER2). By testing the unique genetic and transcriptomic features of these cases, we developed the hypothesis that FGFR4 likely participates in this subtype switching. To evaluate this, we developed 2 FGFR4 genomic signatures using a patient-derived xenograft (PDX) model treated with an FGFR4 inhibitor, which inhibited PDX growth in vivo. Bulk tumor gene expression analysis and single-cell RNA sequencing demonstrated that the inhibition of FGFR4 signaling caused molecular switching. In the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohort, FGFR4-induced and FGFR4-repressed signatures each predicted overall survival. Additionally, the FGFR4-induced signature was an independent prognostic factor beyond subtype and stage. Supervised analysis of 77 primary tumors with paired metastases revealed that the FGFR4-induced signature was significantly higher in luminal/ER . tumor metastases compared with their primaries. Finally, multivariate analysis demonstrated that the FGFR4-induced signature also predicted site-specific metastasis for lung, liver, and brain, but not for bone or lymph nodes. These data identify a link between FGFR4-regulated genes and metastasis, suggesting treatment options for FGFR4-positive patients, whose high expression is not caused by mutation or amplification.

Filiaciones:
Garcia-Recio S:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

Thennavan A:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Sch Dent, Oral & Craniofacial Biomed Program, Chapel Hill, NC 27599 USA

East M:
 Univ N Carolina, Sch Med, Dept Pharmacol, Dept Med, Chapel Hill, NC 27599 USA

Parker J:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

Cejalvo J:
 Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

Garay J:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

Hollern D:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

He X:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

Mott K:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

Galvan P:
 Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

Fan C:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

Selitsky S:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

Coffey A:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

Marron D:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

Braso-Maristany F:
 Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

Burgues O:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain

Albanell J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain

 IMIM Hosp del Mar Med Res Inst, Barcelona, Spain

 Hosp del Mar, Med Oncol Dept, Barcelona, Spain

 Univ Pompeu Fabra, Barcelona, Spain

Rojo F:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain

 Fdn Jimenez Diaz, Madrid, Spain

Lluch A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain

 Hosp Clin Univ Valencia, Valencia, Spain

 Univ Valencia, Biomed Res Inst Incl, Valencia, Spain

de Duenas E:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain

 Hosp Prov Castellon, Castellon de La Plana, Spain

Rosen J:
 Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX USA

Johnson G:
 Univ N Carolina, Sch Med, Dept Pharmacol, Dept Med, Chapel Hill, NC 27599 USA

Carey L:
 Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA

Prat A:
 Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

 SOLTI Breast Canc Res Grp, Barcelona, Spain

Perou C:
 Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA

 Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
ISSN: 00219738





JOURNAL OF CLINICAL INVESTIGATION
Editorial
American Society for Clinical Investigation, 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 130 Número: 9
Páginas: 4871-4887
WOS Id: 000579378900003
ID de PubMed: 32573490

MÉTRICAS